- Home
- GRI
GRI
GRI Bio Inc.
as 07-26-2024 4:00pm EST
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 929.8K | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 208.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.15 - $343.07 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest GRI Bio Inc. News
GRI Breaking Stock News: Dive into GRI Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
GlobeNewswire
15 days ago
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
GlobeNewswire
18 days ago
GRI Bio Regains Compliance with Nasdaq
GlobeNewswire
24 days ago
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
GlobeNewswire
a month ago
GRI Bio to Present at the 8th Annual IPF Summit
GlobeNewswire
a month ago
GRI Bio Announces Closing of $4.0 Million Public Offering
GlobeNewswire
a month ago
GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators
GlobeNewswire
a month ago
GRI Bio Announces Pricing of $4 Million Public Offering
Compare GRI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GRI GRI Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.